Search Results - "Ryadinskaya, L. A."

Epoetin alpha in the treatment of anemia in patients with malignant solid tumors during antitumor drug therapy by Vladimirova, L. Yu, Abramova, N. A., Lyanova, A. A., Storozhakova, A. E., Popova, I. L., Teplyakova, M. A., Tikhanovskaya, N. M., Ryadinskaya, L. A., Kalabanova, E. A., Kabanov, S. N., Udalenkova, I. A.

“…Introduction . Erythropoietin (EPO) application is a pathogenetic method for anemia correction in cancer patients. The purpose of study . Clinical evaluation…”
Get full text

Blood coagulation system state in breast cancer patients that recovered from coronaviral infection after undergoing antitumor medical treatment by L. Yu. Vladimirova, E. M. Frantsiyants, N. A. Abramova, K. A. Novoselova, V. S. Myagkova, O. V. Katelnitskaya, A. E. Storozhakova, I. L. Popova, S. N. Kabanov, N. M. Tikhanovskaya, E. A. Kalabanova, L. A. Ryadinskaya, A. A. Lyanova, M. A. Teplyakova, V. R. Zakharchenko, N. K. Guskova

“…Purpose of the study. An analysis of parameters of the blood coagulation system in breast cancer patients after coronavirus disease.Materials and methods. 50…”
Get full text

Checkpoint inhibitors in non-small cell lung carcinoma therapy for progression to the brain (clinical observation) by Vladimirova, L. Yu, Popova, I. L., Abramova, N. A., Teplyakova, M. A., Tikhanovskaya, N. M., Lianova, A. A., Storozhakova, A. E., Ryadinskaya, L. A., Kabanov, S. N., Kalabanova, E. A.

“…The development of a new area of antitumor drug therapy, immunotherapy using immune checkpoint inhibitors targeting PD-1/PD-L1, has significantly changed…”
Get full text

Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metatases by Vladimirova, L. Yu, Popova, I. L., Abramova, N. A., Teplyakova, M. A., Tikhanovskaya, N. M., Novoselova, K. A., Lyanova, A. A., Ryadinskaya, L. A., Ezhova, M. O., Myagkova, V. S., Strakhova, L. K.

“…Patients with brain metastases of HER2-positive breast cancer (BC) is a special group of patients who are difficult to treat and have a short life expectancy…”
Get full text

Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases) by Vladimirova, L. Yu, Storozhakova, A. Eh, Popova, I. L., Kabanov, S. N., Abramova, N. A., Teplyakova, M. A., Tikhanovskaya, N. M., Novoselova, K. A., Lyanova, A. A., Ryadinskaya, L. A., Myagkova, V. S., Alieva, F. V., Kalabanova, E. A., Svetitskaya, Ya. V., Samaneva, N. Yu, Tishina, A. V.

“…The development of a new direction in anticancer medical therapy – the use of immune checkpoint inhibitors targeting PD-1/ PD-L1 and CTLA-4 – has significantly…”
Get full text

EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER by Kit, O. I., Vladimirova, L. Yu, Kalabanova, E. A., Storozhakova, A. E., Kabanov, S. N., Snezhko, T. A., Mitashok, I. S., Svetitskaya, Ya. V., Samaneva, N. Yu, Kornilova, I. S., Przhedetskiy, Yu. V., Pozdnyakova, V. V., Abramova, N. A., Popova, I. L., Tikhanovskaya, N. M., Lyanova, A. A., Novoselova, K. A., Ryadinskaya, L. A.

“…Background. Breast cancer is one of the most common malignancies and one of the leading causes of cancer deaths among women in the Russian Federation. The…”
Get full text

Fulvestrant in treatment for metastatic breast cancer by Vladimirova, L. Yu, Popova, I. L., Abramova, N. A., Storozhakova, A. E., Tikhanovskaya, N. M., Novoselova, K. A., L’yanova, A. A., Ryadinskaya, L. A., Ezhova, M. O., Teplyakova, M. A., Strakhov, L. K.

“…Background. Metastatic breast cancer is still an incurable disease, and is currently regarded as a chronic process requiring longterm treatment with periodic…”
Get full text

Study of EGFR expression in tumor tissue in patients with locally advanced oral cavity cancer receiving cetuximab therapy by Lyanova, A. A., Vladimirova, L. Yu, Ulianova, E. P., Storozhakova, A. E., Abramova, N. A., Popova, I. L., Teplyakova, M. A., Tikhanovskaya, N. M., Myagkova, V. S., Novoselova, K. A., Ryadinskaya, L. A., Strakhova, L. K., Kalabanova, E. A.

“…Introduction: Squamous cell carcinoma of the oral cavity is one of the most common head and neck cancers with an aggressive course and high mortality rates…”
Get full text

Nab-paclitaxel monotherapy in patients with metastatic breast cancer with visceral crisis: evaluation of efficacy and tolerability in clinical practice by Vladimirova, L. Yu, Novoselova, K. A., Abramova, N. A., Popova, I. L., Tikhanovskaya, N. M., Ryadinskaya, L. A., Lyanova, A. A., Ezhova, M. O., Teplyakova, M. A., Tishina, A. A., Prikhodko, E. V.

“…The authors analysed the efficacy and safety of Nab-paclitaxel (Nab-R) monotherapy in patients with metastatic breast cancer with visceral crisis (VC) in the…”
Get full text

Dynamics of changes in expression of VEGF neoangiogenic factor in tumor tissue bioptates in patients with squamous cell carcinoma of oral mucosa receiving cetuximab treatment and chemotherapy by A. A. Lyanova, L. Yu. Vladimirova, E. P. Ulyanova, N. A. Abramova, A. E. Storozhakova, I. L. Popova, N. M. Tikhanovskaya, M. A. Teplyakova, L. A. Ryadinskaya, I. A. Udalenkova, E. A. Kalabanova, S. N. Kabanov

“…Purpose of the study. An analysis of changes in the expression of the VEGF neoangiogenic factor in the tumor tissue of patients with squamous cell carcinoma of…”
Get full text

Using of multi-kinase inhibitor regorafenib for metastatic colorectal cancer by Kit, O.I., Vladimirova, L.Y., Abramova, N.A., Storozhakova, A.E., Popova, I.L., Tikhanovskaya, N.M., Lyaynova, A.A., Ryadinskaya, L.A.

“…The data of the efficacy and safety regorafenib in the treatment of 7 patients with metastatic colorectal cancer (mCRC) refractory to treatment with…”
Get full text